Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2013 | 8.87 Million USD | -91.93% |
| 2012 | 109.93 Million USD | 155.68% |
| 2011 | 42.99 Million USD | -26.92% |
| 2010 | 58.84 Million USD | -59.31% |
| 2009 | 144.6 Million USD | -8.9% |
| 2008 | 158.73 Million USD | 12.1% |
| 2007 | 141.6 Million USD | 6.4% |
| 2006 | 133.08 Million USD | -23.8% |
| 2005 | 174.65 Million USD | 52.02% |
| 2004 | 114.89 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2014 Q1 | 8.79 Million USD | -0.81% |
| 2014 Q2 | 214 Thousand USD | -97.57% |
| 2013 FY | 8.87 Million USD | -91.93% |
| 2013 Q1 | 81.49 Million USD | -25.87% |
| 2013 Q3 | 16.41 Million USD | -20.27% |
| 2013 Q4 | 8.87 Million USD | -45.95% |
| 2013 Q2 | 20.58 Million USD | -74.74% |
| 2012 Q3 | 67.59 Million USD | 12.88% |
| 2012 Q1 | 57.43 Million USD | 33.57% |
| 2012 FY | 109.93 Million USD | 155.68% |
| 2012 Q4 | 109.93 Million USD | 62.64% |
| 2012 Q2 | 59.87 Million USD | 4.26% |
| 2011 Q4 | 42.99 Million USD | 37.3% |
| 2011 Q3 | 31.31 Million USD | 1.58% |
| 2011 Q1 | 45.84 Million USD | -22.09% |
| 2011 FY | 42.99 Million USD | -26.92% |
| 2011 Q2 | 30.83 Million USD | -32.75% |
| 2010 Q1 | 127.78 Million USD | -11.63% |
| 2010 FY | 58.84 Million USD | -59.31% |
| 2010 Q4 | 58.84 Million USD | -28.37% |
| 2010 Q2 | 104.99 Million USD | -17.83% |
| 2010 Q3 | 82.15 Million USD | -21.76% |
| 2009 FY | 144.6 Million USD | -8.9% |
| 2009 Q1 | 160.73 Million USD | 1.26% |
| 2009 Q2 | 155.11 Million USD | -3.5% |
| 2009 Q3 | 147.66 Million USD | -4.8% |
| 2009 Q4 | 144.6 Million USD | -2.07% |
| 2008 Q4 | 158.73 Million USD | 1.26% |
| 2008 Q1 | 143.73 Million USD | 1.5% |
| 2008 FY | 158.73 Million USD | 12.1% |
| 2008 Q2 | 150.53 Million USD | 4.73% |
| 2008 Q3 | 156.75 Million USD | 4.14% |
| 2007 Q2 | 134.17 Million USD | -0.67% |
| 2007 Q4 | 141.6 Million USD | 5.3% |
| 2007 Q3 | 134.47 Million USD | 0.23% |
| 2007 Q1 | 135.07 Million USD | 1.49% |
| 2007 FY | 141.6 Million USD | 6.4% |
| 2006 Q2 | 302.93 Million USD | 50.61% |
| 2006 Q3 | 281.03 Million USD | -7.23% |
| 2006 Q4 | 133.08 Million USD | -52.64% |
| 2006 Q1 | 201.13 Million USD | 15.17% |
| 2006 FY | 133.08 Million USD | -23.8% |
| 2005 FY | 174.65 Million USD | 52.02% |
| 2005 Q4 | 174.65 Million USD | 0.0% |
| 2004 Q4 | 114.89 Million USD | 0.0% |
| 2004 FY | 114.89 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -32236.966% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 6.285% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 87.759% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -996.818% |
| Rebus Holdings, Inc. | 5.24 Million USD | -69.229% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 84.968% |
| Qrons Inc. | 1.48 Million USD | -495.884% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -623.447% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 88.159% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -19747.414% |
| Skye Bioscience, Inc. | 14.07 Million USD | 36.961% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 83.358% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 7.42% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2004.287% |
| SQZ Biotechnologies Company | 50.03 Million USD | 82.272% |
| Intellipharmaceutics International Inc. | 12 Million USD | 26.129% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -130.33% |
| Mesoblast Limited | 188.44 Million USD | 95.293% |
| Marizyme, Inc. | 26.67 Million USD | 66.745% |
| Genus plc | 485 Million USD | 98.171% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -51.833% |
| Pharming Group N.V. | 244.07 Million USD | 96.365% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -341.315% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -252.538% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -133.447% |
| ContraFect Corporation | 32.53 Million USD | 72.731% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -347.735% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -131.761% |
| IMV Inc. | 37.93 Million USD | 76.614% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 24.683% |
| MultiCell Technologies, Inc. | 1617.67 USD | -548281.314% |
| ONE Bio Corp. | 27.49 Million USD | 67.737% |
| Accustem Sciences Inc. | 1.07 Million USD | -721.968% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 88.541% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -319.419% |
| Q BioMed Inc. | 8.13 Million USD | -9.075% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 89.304% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -72.385% |
| Biomind Labs Inc. | 1.49 Million USD | -491.948% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 92.528% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 1.893% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 51.797% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -518.679% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6143.006% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4310.887% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -54.39% |
| GB Sciences, Inc. | 5.41 Million USD | -63.745% |
| Alpha Cognition Inc. | 7.16 Million USD | -23.814% |
| HST Global, Inc. | 593.59 Thousand USD | -1394.458% |
| CSL Limited | 18.62 Billion USD | 99.952% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -604.499% |
| Halberd Corporation | 728.71 Thousand USD | -1117.342% |
| Enzolytics Inc. | 365.26 Million USD | 97.571% |
| Agentix Corp. | 2.51 Million USD | -253.348% |
| Resverlogix Corp. | 67.39 Million USD | 86.837% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -957.668% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.006% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -417.561% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 64.152% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 25.473% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -142.036% |
| AVAX Technologies, Inc. | 3.99 Million USD | -122.122% |
| Zenith Capital Corp. | 27.56 Thousand USD | -32077.446% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.331% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3617.097% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -137.554% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1202.961% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -227.145% |
| Kadimastem Ltd | 3.5 Million USD | -153.105% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -13154.344% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 82.351% |
| BioStem Technologies, Inc. | 15.9 Million USD | 44.224% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1808.978% |
| LadRx Corporation | 2.2 Million USD | -303.131% |
| Cell Source, Inc. | 15.8 Million USD | 43.878% |
| Regen BioPharma, Inc. | 5.45 Million USD | -62.543% |
| Regen BioPharma, Inc. | 5.45 Million USD | -62.543% |
| NovAccess Global Inc. | 7.86 Million USD | -12.852% |
| Itoco Inc. | 1.65 Million USD | -436.612% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -332.402% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -46.652% |
| Mobile Lads Corp. | 1.31 Million USD | -575.373% |
| CytoDyn Inc. | 127.89 Million USD | 93.064% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -21122.996% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -466.339% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 19.685% |
| SYBLEU INC | 681.41 Thousand USD | -1201.854% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -45.381% |
| International Stem Cell Corporation | 5.27 Million USD | -68.107% |
| Bioxytran, Inc. | 3.24 Million USD | -172.996% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1317.525% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -92.133% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 78.361% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 60.157% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -337.99% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -61.939% |
| Neutra Corp. | 973.52 Thousand USD | -811.221% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 69.426% |
| PureTech Health plc | 125.58 Million USD | 92.936% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -136.111% |
| IXICO plc | 1.9 Million USD | -366.823% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 56.788% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.414% |
| CSL Limited | 18.62 Billion USD | 99.952% |
| Cellectis S.A. | 249.36 Million USD | 96.443% |